PAVmed (PAVM) to Release Earnings on Thursday

PAVmed (NASDAQ:PAVM) will be announcing its earnings results before the market opens on Thursday, November 14th. Analysts expect the company to announce earnings of ($1.30) per share for the quarter.

PAVmed (NASDAQ:PAVM) last issued its quarterly earnings results on Tuesday, August 13th. The company reported ($0.84) earnings per share for the quarter. The firm had revenue of $0.98 million during the quarter. On average, analysts expect PAVmed to post $-5 EPS for the current fiscal year and $-5 EPS for the next fiscal year.

PAVmed Price Performance

Shares of NASDAQ:PAVM opened at $1.12 on Tuesday. PAVmed has a 1-year low of $0.60 and a 1-year high of $4.88. The business has a fifty day moving average price of $1.23 and a 200-day moving average price of $1.20. The company has a market capitalization of $11.66 million, a PE ratio of -0.14 and a beta of 0.69.

Wall Street Analyst Weigh In

Separately, Ascendiant Capital Markets reduced their price target on PAVmed from $22.00 to $21.00 and set a “buy” rating for the company in a report on Tuesday, September 10th.

PAVmed Company Profile

PAVmed Inc focuses on acquiring, developing, and commercializing novel products that target unmet needs in the United States. The company's lead products include CarpX, a patented, single-use, disposable, and minimally invasive surgical device for use in the treatment of carpal tunnel syndrome; EsoCheck Esophageal Cell Collection Device, which consists of diagnostic test that serves as a testing tool for preventing esophageal adenocarcinoma deaths, through early detection of esophageal precancer in at-risk gastroesophageal reflux disease, including chronic heartburn and acid reflux or simply reflux in patients; and EsoGuard, a bisulfite-converted next-generation sequencing DNA assay performed on surface esophageal cells collected with EsoCheck.